Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study
Christelle Nilles(Fondation de Rothschild), Aurélia Poujois(Fondation Ophtalmologique Adolphe de Rothschild), Edouard Bardou‐Jacquet(Inserm), Mickaël Alexandre Obadia(Fondation Ophtalmologique Adolphe de Rothschild), Corinne Collet(Northwestern University), Frédérique Fluchère(Hôpital de la Timone), Rodolphe Sobesky(Inserm), Victor de Lédinghen(Hôpital Cardiologique du Haut-Lévêque), Fabienne Ory‐Magne(Inserm), France Woimant(Fondation de Rothschild), Caroline Moreau(Hôpital Européen Georges-Pompidou), Nouzha Oussedik‐Djebrani(Hôpital Lariboisière), Claire Vanlemmens(Centre Hospitalier Universitaire de Besançon), Jérôme Dumortier(Hospices Civils de Lyon), Chloé Laurencin(Hôpital Femme Mère Enfant), Olivier Guillaud(Hospices Civils de Lyon)
Cited by 26
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
|New England Journal of Medicine|2017|565
Trial of Lixisenatide in Early Parkinson’s Disease
|New England Journal of Medicine|2024|302